CLAIRIgene’s Alzheimer’s program received its first STTR award from the National Institute on Aging of the National Institutes of Health for the project entitled, “APOE-targeted therapy for precision medicine in late onset Alzheimer’s disease: A novel epigenome editing approach for downregulation of APOEe4 expression”

Aug 2022